Plasmid DNA Manufacturing Market To Reach $6.70 Billion By 2030

Plasmid DNA Manufacturing Market Growth & Trends

The global plasmid DNA manufacturing market size is expected to reach USD 6.70 billion by 2030, expanding at a CAGR of 21.44% from 2025 to 2030, according to a new report by Grand View Research, Inc. The rising prevalence of chronic diseases, combined with the wide application scope of plasmid DNA in the healthcare industry is expected to drive the industry growth. Plasmid DNA can be used directly for therapeutic applications, such as the production of vaccine antigens or gene therapy. Moreover, it can be utilized for various research purposes, such as gene cloning, gene mapping, etc. The rising number of patients choosing gene therapy is expected to drive industry growth in the coming years.

According to clinicaltrials.gov, the number of cell & gene therapies across global pipeline programs (Phase I to Phase III trials) increased from 289 in 2018 to 327 in 2022. Furthermore, the U.S. FDA provides constant support for innovations in the advanced therapy arena via several policies concerning product manufacturing. With increased cell and gene therapy products, the industry will see an increased need for manufacturing plasmid DNA on a larger scale. The COVID-19 pandemic is anticipated to positively impact industry growth. For instance, in September 2021, India approved the first COVID-19 DNA vaccine. It is the world’s first COVID-19 DNA vaccine manufactured in partnership with DBT-BIRAC as part of Mission COVID Suraksha.

Circular DNA is used in India’s ZyCoV-D vaccination to protect against COVID-19 infection. Furthermore, key entities in the global industry are undertaking various strategic initiatives to strengthen their market presence, which is also expected to propel growth. For instance, in June 2022, BioCina announced the expansion of the production of plasmid DNA in a new dedicated GMP suite to its offering of CDMO services. The suite has a single-use fermentation capacity of up to 300 L and appropriately scaled downstream processing machinery.

 Request a free sample copy or view report summary: Plasmid DNA Manufacturing Market Report

Plasmid DNA Manufacturing Market Report Highlights

• MP-grade plasmid DNA manufacturing dominated the market in 2024 with a share of 86.29% and is expected to grow at the fastest CAGR over the forecast period.

• The clinical therapeutics segment held the largest market share of 54.6% in 2024. Plasmid DNA is currently increasing in importance for clinical research applications in genetic vaccination and gene therapy.

• The cell & gene therapy segment held the largest market share of 54.4% in 2024. This high share can be attributed to the fact that gene therapy is broadly applied in the treatment of several inherited and genetic diseases.

• The cancer segment held the largest market share of 40.0% in 2024 and is expected to witness the fastest CAGR from 2025 to 2030.

• The North America Plasmid DNA manufacturing market held the largest revenue share of 43.43% of the global market in 2024.

Plasmid DNA Manufacturing Market Segmentation

Grand View Research has segmented the global plasmid DNA manufacturing market on the basis of service, application, end use, and country:

Plasmid DNA Manufacturing Grade Outlook (Revenue, USD Million, 2018 - 2030)

• R&D Grade

  • Viral Vector Development

    • AAV

    • Lentivirus

    • Adenovirus

    • Retrovirus

    • Others

  • mRNA Development

  • Antibody Development

  • DNA Vaccine Development

  • Others

• GMP Grade

Plasmid DNA Manufacturing Development Phase Outlook (Revenue, USD Million, 2018 - 2030)

• Pre-Clinical Therapeutics

• Clinical Therapeutics

• Marketed Therapeutics 

Plasmid DNA Manufacturing Application Outlook (Revenue, USD Million, 2018 - 2030)

• DNA Vaccines

• Cell & Gene Therapy

• Immunotherapy

• Others

Plasmid DNA Manufacturing Disease Outlook (Revenue, USD Million, 2018 - 2030)

• Infectious Disease

• Cancer

• Genetic Disorder

• Others

Plasmid DNA Manufacturing Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • Germany

  • UK

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • China

  • Japan

  • India

  • South Korea

  • Australia

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players of Plasmid DNA Manufacturing Market

• Charles River Laboratories

• VGXI, Inc.

• Danaher (Aldevron)

• Kaneka Corp.

• Nature Technology

• Cell and Gene Therapy Catapult

• Eurofins Genomics

• Lonza

• Luminous BioSciences, LLC

• Akron Biotech